Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Lymphoma
•
Hematology
Have you utilized a dose-reduced approach for elderly patients receiving frontline Pola-R-CHP similar to R-miniCHOP?
Related Questions
How would you consolidate a patient with primary refractory double hit lymphoma with secondary CNS involvement?
Is there a role for thiotepa-based auto transplant for consolidation in PCNSL if the patient had progression on both MTX and Ara-C?
How do CLL patients with downstream treatment-resistant mutations such as PLCG2 respond to pirtobrutinib?
What post-protocol therapies did patients on the BRUIN trial in CLL receive, and how did these therapies impact outcomes?
Given the data from SWOG 1826 suggesting that Nivo-AVD is likely the preferred regimen for advanced Hodgkin lymphoma patients, are there scenarios where BV-AVD may still be preferred?
How would you approach fertility preservation in a young patient with DLBCL requiring R-CHOP?
How would you treat an elderly male with history of mantle cell lymphoma who relapsed after chemoimmunotherapy and cBTKi w/ multiple co-morbidities including CKD and CHF w/ low EF?
How would you manage a stage IE Burkitt lymphoma with stable disease after three cycle of DA-R-EPOCH?
How do you time CSF analysis for suspected CNS lymphoma in patients who are on steroids?
How would you manage a patient with p53 mutated MCL who has progressed after a BTKi and CAR-T with a CD20 negative clone?
